Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: A nested case-control study

Arthritis and Rheumatology

Volumn 67, Issue 11, 2015, Pages 2845-2854

  Mantel, Ängla ^a   Holmqvist, Marie ^a   Nyberg, Fredrik ^b,c   Tornling, Göran ^a   Frisell, Thomas ^a   Alfredsson, Lars ^a   Askling, Johan ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPITOPE; METHOTREXATE; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DRUG EXPOSURE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GENETIC MARKER; HEALTH ASSESSMENT QUESTIONNAIRE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL LEAVE; MEDICAL RECORD REVIEW; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SMOKING; AGED; ARTHRITIS, RHEUMATOID; BLOOD; COMPLICATION; INCIDENCE; REGISTER; RISK FACTOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGISTRIES; RHEUMATOID FACTOR; RISK FACTORS;

EID: 84946011481     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39267     Document Type: Article

References (50)

1. Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, et al., Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008; 67: 64-9.
2. Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A., High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-45.
3. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Pineiro A, Garcia-Porrua C, Miranda-Filloy JA, et al., HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 125-32.
4. Teruel M, Martin JE, Gonzalez-Juanatey C, Lopez-Mejias R, Miranda-Filloy JA, Blanco R, et al., Association of acid phosphatase locus 1∗C allele with the risk of cardiovascular events in rheumatoid arthritis patients. Arthritis Res Ther 2011; 13: R116.
5. Mattey DL, Thomson W, Ollier WE, Batley M, Davies PG, Gough AK, et al., Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the Early Rheumatoid Arthritis Study. Arthritis Rheum 2007; 56: 1408-16.
6. Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, Smith JP, Milionis HJ, Douglas KM, et al., Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009; 204: 178-83.
7. Panoulas VF, Nikas SN, Smith JP, Douglas KM, Nightingale P, Milionis HJ, et al., Lymphotoxin 252A>G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1550-6.
8. Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Rodriguez L, Miranda-Filloy JA, Fernandez-Gutierrez B, et al., A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther 2010; 12: R71.
9. Farragher TM, Goodson NJ, Naseem H, Silman AJ, Thomson W, Symmons D, et al., Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008; 58: 359-69.
10. Arlestig L, Jonsson SW, Stegmayr B, Rantapaa-Dahlqvist S., Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 866-71.
11. Ajeganova S, Andersson ML, Frostegard J, Hafstrom I., Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J Rheumatol 2013; 40: 1958-66.
12. Farragher TM, Lunt M, Bunn DK, Silman AJ, Symmons DP., Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2007; 66: 486-92.
13. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE., Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722-32.
14. Liang KP, Maradit Kremers H, Crowson CS, Snyder MR, Therneau TM, Roger VL, et al., Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009; 36: 2462-9.
15. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, Gonzalez-Díaz de Rabago E, Sanchez-Ramon S, Rodríguez-Mahou M, et al., Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009; 61: 419-24.
16. Rho YH, Chung CP, Oeser A, Solus J, Asanuma Y, Sokka T, et al., Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009; 61: 1580-5.
17. Giles JT, Szklo M, Post W, Petri M, Blumenthal RS, Lam G, et al., Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. Arthritis Res Ther 2009; 11: R36.
18. Innala L, Moller B, Ljung L, Magnusson S, Smedby T, Sodergren A, et al., Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011; 13: R131.
19. Turesson C, McClelland RL, Christianson TJ, Matteson EL., Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 70-5.
20. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S., Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 1999; 26: 2562-71.
21. Radovits BJ, Popa-Diaconu DA, Popa C, Eijsbouts A, Laan RF, van Riel PL, et al., Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1271-6.
22. Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ., Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005; 52: 2293-9.
23. Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, et al., The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010; 49: 295-307.
24. Ruyssen-Witrand A, Fautrel B, Saraux A, Le Loet X, Pham T., Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011; 78: 23-30.
25. Holmqvist ME, Wedren S, Jacobsson LT, Klareskog L, Nyberg F, Rantapaa-Dahlqvist S, et al., No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum 2009; 60: 2861-9.
26. Holmqvist ME, Wedren S, Jacobsson LT, Klareskog L, Nyberg F, Rantapaa-Dahlqvist S, et al., Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 2010; 268: 578-85.
27. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al., The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011; 70: 929-34.
28. Holmqvist ME, Neovius M, Eriksson J, Mantel A, Wallberg-Jonsson S, Jacobsson LT, et al., Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 2012; 308: 1350-6.
29. Holmqvist M, Gransmark E, Mantel A, Alfredsson L, Jacobsson LT, Wallberg-Jonsson S, et al., Occurrence and relative risk of stroke in incident and prevalent contemporary rheumatoid arthritis. Ann Rheum Dis 2013; 72: 541-6.
30. Alpert JS, Thygesen K, Antman E, Bassand JP., Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction [published erratum appears in J Am Coll Cardiol 2001;37:973]. J Am Coll Cardiol 2000; 36: 959-69.
31. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
32. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al., 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
33. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
34. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.
35. Fries JF, Spitz PW, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
36. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al., and the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38-46.
37. Libby P., Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 2045-51.
38. Libby P., Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008; 121 Suppl 1: S21-31.
39. Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367: 1310-20.
40. Medin J, Nordlund A, Ekberg K., Sick leave, disability pension and health-care-seeking behaviour prior to stroke, among people aged 30-65: a case-control study. Brain Inj 2007; 21: 457-63.
41. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Wilson M, Nevill AM, Koutedakis Y, et al., Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil 2009; 16: 188-94.
42. Stavropoulos-Kalinoglou A, Metsios GS, Veldhuijzen van Zanten JJ, Nightingale P, Kitas GD, Koutedakis Y., Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1819-25.
43. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al., Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 427-30.
44. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van 't Hof M, et al., The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 1831-5.
45. Gonzalez A, Icen M, Maradit Kremers H, Crowson CS, Davis JM III, Therneau TM, et al., Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol 2008; 35: 1009-14.
46. Bergstrom U, Jacobsson LT, Turesson C., Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmo, Sweden. Rheumatology (Oxford) 2009; 48: 1600-5.
47. Cambridge G, Acharya J, Cooper JA, Edwards JC, Humphries SE., Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 2013; 228: 243-6.
48. Arnab B, Biswadip G, Arindam P, Shyamash M, Anirban G, Rajan P., Anti-CCP antibody in patients with established rheumatoid arthritis: does it predict adverse cardiovascular profile? J Cardiovasc Dis Res 2013; 4: 102-6.
49. Hughes-Austin JM, Young KA, Deane KD, Weisman MH, Buckner JH, Mikuls TR, et al., Antibodies to citrullinated enolase, fibrinogen, and vimentin are associated with markers of endothelial dysfunction in first-degree relatives of patients with rheumatoid arthritis: the Studies of the Etiology of Rheumatoid Arthritis [abstract]. Arthritis Rheum 2013; 65 Suppl: S1133-4.
50. Sokolove J, Brennan MJ, Sharpe O, Lahey LJ, Kao AH, Krishnan E, et al., Citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 2013; 65: 1719-24.